Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease

Brain Research

Volumn 1367, Issue , 2011, Pages 310-318

  Xiao, Danqing ^a   Cassin, Jared J ^a   Healy, Brian ^a   Burdett, Thomas C ^a   Chen, Jiang Fan ^b   Fredholm, Bertil B ^c   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

6 hydroxydopamine; A1 and A2A knockout; Adenosine receptor antagonist; Basal ganglia; Preprodynorphin; Preproenkephalin

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; CAFFEINE; LEVODOPA; PREPROENKEPHALIN; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; DYNORPHIN; ENKEPHALIN; MESSENGER RNA; OXIDOPAMINE; PRE PRODYNORPHIN; PRE-PRODYNORPHIN; PROTEIN PRECURSOR;

ARTICLE; DRUG EFFECT; DYSKINESIA; GENE DELETION; GENE EXPRESSION; MOUSE; NERVE CELL; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CORPUS STRIATUM; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; NONPARAMETRIC TEST; TIME;

MUS; PARKINSONIA;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; CAFFEINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; GENE EXPRESSION REGULATION; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDOPAMINE; PARKINSON DISEASE; PROTEIN PRECURSORS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 78650514763     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.08.099     Document Type: Article

References (53)

1. A.F. Ambrosio, J.O. Malva, A.P. Carvalho, and C.M. Carvalho Modulation of Ca2+ channels by activation of adenosine A1 receptors in rat striatal glutamatergic nerve terminals Neurosci. Lett. 220 1996 163 166
2. Banbury Conference Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice Neuron 19 1997 755 759
3. E. Bastia, Y.H. Xu, A.C. Scibelli, Y.J. Day, J. Linden, J.F. Chen, and M.A. Schwarzschild A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization Neuropsychopharmacology 30 2005 891 900
4. P.J. Bedard, P.J. Blanchet, D. Levesque, J.J. Soghomonian, R. Grondin, M. Morissette, M. Goulet, F. Calon, P. Falardeau, B. Gomez-Mancilla, J.P. Doucet, G.S. Robertson, and T. DiPaolo Pathophysiology of l-dopa-induced dyskinesias Mov. Disord. 14 Suppl 1 1999 4 8
5. C.L. Benn, L.A. Farrell, and J.H. Cha Neurotransmitter receptor analysis in transgenic mouse models Meth. Mol. Biol. 277 2004 231 260
6. F. Bibbiani, J.D. Oh, J.P. Petzer, N. Castagnoli Jr., J.F. Chen, M.A. Schwarzschild, and T.N. Chase A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease Exp. Neurol. 184 2003 285 294
7. J. Borycz, M.F. Pereira, A. Melani, R.J. Rodrigues, A. Kofalvi, L. Panlilio, F. Pedata, S.R. Goldberg, R.A. Cunha, and S. Ferre Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments J. Neurochem. 101 2007 355 363
8. A.R. Carta, A. Pinna, O. Cauli, and M. Morelli Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent l-dopa and A2A receptor blockade plus l-dopa in dopamine-denervated rats Synapse 44 2002 166 174
9. A.R. Carta, A. Kachroo, N. Schintu, K. Xu, M.A. Schwarzschild, J. Wardas, and M. Morelli Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease J. Neurochem. 111 2009 1478 1489
10. M.A. Cenci, and M. Lundblad Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease M. LeDoux, Animal models of movement disorders, Vol. Chapter B7 2005 Elsevier Inc. Boston, MA 193 208
11. M.A. Cenci, and M. Lundblad Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice Curr. Protoc. Neurosci. 2007 Chapter 9, Unit 9 25.
12. M.A. Cenci, C.S. Lee, and A. Bjorklund L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
13. J.F. Chen The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment Drug News Perspect. 16 2003 597 604
14. J.F. Chen, Z. Huang, J. Ma, J. Zhu, R. Moratalla, D. Standaert, M.A. Moskowitz, J.S. Fink, and M.A. Schwarzschild A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice J. Neurosci. 19 1999 9192 9200
15. J.F. Chen, R. Moratalla, F. Impagnatiello, D.K. Grandy, B. Cuellar, M. Rubinstein, M.A. Beilstein, E. Hackett, J.S. Fink, M.J. Low, E. Ongini, and M.A. Schwarzschild The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice Proc. Natl. Acad. Sci. U. S. A. 98 2001 1970 1975
16. J.F. Chen, K. Xu, J.P. Petzer, R. Staal, Y.H. Xu, M. Beilstein, P.K. Sonsalla, K. Castagnoli, N. Castagnoli Jr., and M.A. Schwarzschild Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease J. Neurosci. 21 2001 RC143
17. J.F. Chen, P.K. Sonsalla, F. Pedata, A. Melani, M.R. Domenici, P. Popoli, J. Geiger, L.V. Lopes, and A. de Mendonca Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation Prog. Neurobiol. 83 2007 310 331
18. F. Ciruela, V. Casado, R.J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N. Rebola, S.R. Goldberg, J. Mallol, A. Cortes, E.I. Canela, J.F. Lopez-Gimenez, G. Milligan, C. Lluis, R.A. Cunha, S. Ferre, and R. Franco Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers J. Neurosci. 26 2006 2080 2087
19. T.V. Dunwiddie, and S.A. Masino The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 24 2001 31 55
20. J. Fastbom, A. Pazos, A. Probst, and J.M. Palacios Adenosine A1 receptors in the human brain: a quantitative autoradiographic study Neuroscience 22 1987 827 839
21. S. Ferre, W.T. O'Connor, P. Svenningsson, L. Bjorklund, J. Lindberg, B. Tinner, I. Stromberg, M. Goldstein, S.O. Ogren, U. Ungerstedt, B.B. Fredholm, and K. Fuxe Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopenduncular pathway and its modulation by adenosine A1 receptor-mediated mechanisms Eur. J. Neurosci. 8 1996 1545 1553
22. S. Ferre, B.B. Fredholm, M. Morelli, P. Popoli, and K. Fuxe Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci. 20 1997 482 487
23. K. Franklin, and G. Paxinos The mouse brain in stereotaxic coordinates 1997 Academic press San Diego
24. S. Fredduzzi, R. Moratalla, A. Monopoli, B. Cuellar, K. Xu, E. Ongini, F. Impagnatiello, M.A. Schwarzschild, and J.F. Chen Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors J. Neurosci. 22 2002 1054 1062
25. B.B. Fredholm, and T.V. Dunwiddie How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 9 1988 130 134
26. B.B. Fredholm, K. Battig, J. Holmen, A. Nehlig, and E.E. Zvartau Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol. Rev. 51 1999 83 133
27. B.B. Fredholm, R.A. Cunha, and P. Svenningsson Pharmacology of adenosine A2A receptors and therapeutic applications Curr. Top. Med. Chem. 3 2003 413 426
28. B.B. Fredholm, J.F. Chen, R.A. Cunha, P. Svenningsson, and J.M. Vaugeois Adenosine and brain function Int. Rev. Neurobiol. 63 2005 191 270
29. B. Henry, A.R. Crossman, and J.M. Brotchie Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat Exp. Neurol. 155 1999 204 220
30. K. Ikeda, M. Kurokawa, S. Aoyama, and Y. Kuwana Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease J. Neurochem. 80 2002 262 270
31. S. Jin, B. Johansson, and B.B. Fredholm Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices J. Pharmacol. Exp. Ther. 267 1993 801 808
32. B. Johansson, V. Georgiev, K. Lindstrom, and B.B. Fredholm A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment Brain Res. 762 1997 153 164
33. A. Kachroo, L.R. Orlando, D.K. Grandy, J.F. Chen, A.B. Young, and M.A. Schwarzschild Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice J. Neurosci. 25 2005 10414 10419
34. M. Karcz-Kubicha, K. Antoniou, A. Terasmaa, D. Quarta, M. Solinas, Z. Justinova, A. Pezzola, R. Reggio, C.E. Muller, K. Fuxe, S.R. Goldberg, P. Popoli, and S. Ferre Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration Neuropsychopharmacology 28 2003 1281 1291
35. H. Kase New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia Biosci. Biotechnol. Biochem. 65 2001 1447 1457
36. L.V. Lopes, R.A. Cunha, B. Kull, B.B. Fredholm, and J.A. Ribeiro Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition Neuroscience 112 2002 319 329
37. M. Lundblad, B. Picconi, H. Lindgren, and M.A. Cenci A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 16 2004 110 123
38. M. Morelli, T. Di Paolo, J. Wardas, F. Calon, D. Xiao, and M.A. Schwarzschild Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications Prog. Neurobiol. 83 2007 293 309
39. M. Morissette, M. Dridi, F. Calon, A. Hadj Tahar, L.T. Meltzer, P.J. Bedard, and T. Di Paolo Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin Mov. Disord. 21 2006 9 17
40. M.E. Olah, and G.L. Stiles Adenosine receptor subtypes: characterization and therapeutic regulation Annu. Rev. Pharmacol. Toxicol. 35 1995 581 606
41. M. Pierri, E. Vaudano, T. Sager, and U. Englund KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacology 48 2005 517 524
42. P. Ravenscroft, S. Chalon, J.M. Brotchie, and A.R. Crossman Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia Exp. Neurol. 185 2004 36 46
43. L.H. Schneider, C.A. Watson, J. Gibbs, and G.P. Smith Infra-additivity of combined treatments with selective D1 and D2 receptor antagonists for inhibiting sucrose reinforcement Brain Res. 550 1991 122 124
44. M.A. Schwarzschild, J.F. Chen, M. Tennis, S. Messing, C. Kamp, A. Ascherio, R.G. Holloway, K. Marek, C.M. Tanner, M. McDermott, A.E. Lang and the Parkinson Study Group Relating caffeine consumption to Parkinson's disease progression and dyskinesias development Mov. Disord. 18 2003 1682 1683
45. B.C. Tel, B.Y. Zeng, C. Cannizzaro, R.K. Pearce, S. Rose, and P. Jenner Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets Neuroscience 115 2002 1047 1058
46. M. Tohyama, and K. Takatsuji Atlas of neuroactive substances and their receptors in the rat 1998 Oxford University Press New York
47. D. van Calker, M. Muller, and B. Hamprecht Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells J. Neurochem. 33 1979 999 1005
48. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
49. D. Xiao, E. Bastia, Y.H. Xu, C.L. Benn, J.H. Cha, T.S. Peterson, J.F. Chen, and M.A. Schwarzschild Forebrain adenosine A2A receptors contribute to L-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice J. Neurosci. 26 2006 13548 13555
50. K. Xu, E. Bastia, and M. Schwarzschild Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease Pharmacol. Ther. 105 2005 267 310
51. K. Xu, Y. Xu, D. Brown-Jermyn, J.F. Chen, A. Ascherio, D.E. Dluzen, and M.A. Schwarzschild Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease J. Neurosci. 26 2006 535 541
52. L. Yu, M.A. Schwarzschild, and J.F. Chen Cross-sensitization between caffeine- and l-dopa-induced behaviors in hemiparkinsonian mice Neurosci. Lett. 393 2006 31 35
53. B.Y. Zeng, R.K. Pearce, G.M. MacKenzie, and P. Jenner Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA Eur. J. Neurosci. 12 2000 1096 1104